Levetiracetam in Patients With Impulsive Aggression: A Double-Blind, Placebo-Controlled Trial
J Clin Psychiatry 2008;69(2):310-315
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: There are few controlled studies evaluating drug
treatment for impulsive aggression. The objective of this study was to evaluate
levetiracetam in patients with impulsive aggression, and whether diagnosis or
other baseline characteristics predict response.
Method: Outpatients with clinically significant impulsive
aggression (meeting Coccaro et al. revised criteria for intermittent explosive
disorder), without other psychiatric symptomatology clearly requiring
treatment, were randomly assigned to levetiracetam or placebo, double-blind,
for 10 weeks, at a variable dose with a maximum dose of 3000 mg/day. The
primary efficacy measure was change in the total aggression score from the
revised Overt Aggression Scale-Modified. The study was conducted from September
2005 to July 2006.
Results: Of 40 patients (20 in each treatment group), 34
completed at least 4 weeks of treatment with double-blind medication. There was
no overall statistical evidence of levetiracetam benefit, and no subgroup more
responsive to levetiracetam could be identified.
Conclusions: Levetiracetam was not as efficacious as
oxcarbazepine was in a prior similar study. Additional studies of medications
for impulsive aggression seem warranted.